Cargando…
Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report
BACKGROUND: Ozurdex is a 700 mcg dexamethasone intravitreal implant, approved for the management of macular edema secondary to retinal vein occlusion, and other related pathoglogiesAnterior chamber dislocation of Ozurdex represents an uncommon complication of the intravitreal injection, which can be...
Autores principales: | Pacella, Fernanda, Agostinelli, Enzo, Carlesimo, Sandra Cinzia, Nebbioso, Marcella, Secondi, Roberto, Forastiere, Michele, Pacella, Elena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5062904/ https://www.ncbi.nlm.nih.gov/pubmed/27733187 http://dx.doi.org/10.1186/s13256-016-1077-2 |
Ejemplares similares
-
Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema
por: Pacella, Elena, et al.
Publicado: (2013) -
Effects of Repeated Intravitreal Injections of Dexamethasone Implants on Intraocular Pressure: A 4-Year Study
por: Pacella, Elena, et al.
Publicado: (2020) -
Management of Anterior Chamber Migration of Dexamethasone Intravitreal Implant
por: Ha, Jun Young, et al.
Publicado: (2017) -
Management and Complications of Dexamethasone Intravitreal Implant
Migration Into the Anterior Chamber
por: Betsch, Devin M., et al.
Publicado: (2022) -
Anterior chamber migration of intravitreal dexamethasone implant in glued intraocular lens
por: Kumar, Dhivya Ashok, et al.
Publicado: (2019)